State of Wisconsin Investment Board Has $65.16 Million Stock Holdings in Stryker Corporation $SYK

State of Wisconsin Investment Board cut its position in Stryker Corporation (NYSE:SYK) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 185,388 shares of the medical technology company’s stock after selling 2,605 shares during the period. State of Wisconsin Investment Board’s holdings in Stryker were worth $65,158,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Czech National Bank boosted its stake in Stryker by 3.9% during the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Davis R M Inc. boosted its stake in Stryker by 1.8% during the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after purchasing an additional 2,512 shares during the last quarter. Kepler Cheuvreux Suisse SA acquired a new position in Stryker during the 3rd quarter valued at about $27,952,000. Daymark Wealth Partners LLC boosted its stake in Stryker by 436.0% during the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after purchasing an additional 37,307 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC boosted its stake in Stryker by 265.2% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after purchasing an additional 6,774 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $310.71 on Wednesday. The company’s 50-day moving average is $315.51 and its 200 day moving average is $342.88. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The company has a market capitalization of $119.11 billion, a P/E ratio of 35.96, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Ratings Changes

A number of research firms have issued reports on SYK. Needham & Company LLC cut their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Evercore set a $355.00 price target on Stryker in a research note on Friday, May 1st. Citigroup cut their price target on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Sanford C. Bernstein set a $410.00 price target on Stryker in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. dropped their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.